Literature DB >> 952719

Tumour-directed leucocyte migration inhibition in operable breast cancer: additional clinical correlations.

B M Jones, C E Connolly, P Isaacson, D T Turner, A R Turnbull.   

Abstract

Entities:  

Mesh:

Year:  1976        PMID: 952719      PMCID: PMC2025140          DOI: 10.1038/bjc.1976.128

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  6 in total

1.  In vitro study of cellular immunity against autochthonous human cancer.

Authors:  A Segall; O Weiler; J Genin; J Lacour; F Lacour
Journal:  Int J Cancer       Date:  1972-03-15       Impact factor: 7.396

2.  Inhibition of leukocyte migration by tumor-associated antigens in soluble extracts of human breast carcinoma.

Authors:  J L McCoy; L F Jerome; J H Dean; G B Cannon; T C Alford; T Doering; R B Herberman
Journal:  J Natl Cancer Inst       Date:  1974-07       Impact factor: 13.506

3.  The cellular immune response to carcinoma of the urinary bladder: correlation to clinical stage and treatment.

Authors:  C O'Toole; B Unsgaard; L E Almgård; B Johansson
Journal:  Br J Cancer Suppl       Date:  1973-08

4.  Effect of autologous mammary tumour extracts on human leukocyte migration in vitro.

Authors:  V Andersen; O Bjerrum; G Bendixen; T Schiodt; I Dissing
Journal:  Int J Cancer       Date:  1970-05-15       Impact factor: 7.396

5.  In vitro cellular immunity in mammary carcinoma.

Authors:  B M Jones; A R Turnbull
Journal:  Br J Cancer       Date:  1974-04       Impact factor: 7.640

6.  Horizontal studies of cell mediated immune reactions to autologous tumour antigens in patients with operable mammary carcinoma.

Authors:  B M Jones; A R Turnbull
Journal:  Br J Cancer       Date:  1975-09       Impact factor: 7.640

  6 in total
  1 in total

1.  Mechanisms of leucocyte migration inhibition by breast tumour cell fractions.

Authors:  B M Jones
Journal:  Br J Cancer       Date:  1976-07       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.